Fairfield Market Research
Lupus Therapeutics Market

Lupus Therapeutics Market

Global Industry Analysis (2018 - 2021) - Growth Trends and Market Forecast (2022 - 2029)

Published Date: Upcoming | Format:

Industry: Pharmaceuticals & Biotechnology | Author Name: Sayali


Request TOC More Information

Increasing Lupus Prevalence and Number of Research & Development Activities to Fuel Growth of Lupus Therapeutics Market

The rising prevalence of lupus disorders worldwide is one of the most important factors influencing the growth of the global lupus therapeutics market. According to an article published in the Lupus Science and Medicine journal in April 2021, the incidence and prevalence of Systemic Lupus Erythematosus (SLE) in Europe in 2020 were estimated to be around 0.3 to 5.1 per 100 000 per year and 6.5 to 85 per 100 000 population, respectively.

Since COVID-19 is linked to lupus, the COVID-19 pandemic is predicted to have a beneficial impact on the overall growth of the lupus treatments industry. According to a paper published in the Journal of Medical Case Reports in January 2021, the link between COVID-19 and lupus has yet to be established, but it suggests that COVID-19 could be a potential agent that causes systemic lupus erythematous by creating autoantibodies. The same source also cites a case report of a 39-year-old Iranian man who was the first to develop SLE after being exposed to COVID-19.

The market's expansion is being fuelled by an increase in the number of R&D activities. This will provide beneficial opportunities for the growth of the lupus therapeutic market. Additionally, rising drug approvals and launches will accelerate the market's growth rate. Furthermore, rising investment in the development of advanced technologies, as well as an increase in the number of emerging markets, will provide beneficial opportunities for the growth of the lupus therapeutic market during the forecast period.  For instance, in November 2021, AstraZeneca, a biopharmaceutical company announced positive results from its TULIP Phase 3 clinical trial programme (focused on determining the efficacy and safety of Anifrolumab), stating that Saphnelo (anifrolumab), a human monoclonal antibody, reduced SLE more than standard therapy alone.

Increasing Approvals of Clinical Trials for Systemic Lupus Erythematous (SLE) to Fuel Lupus Therapeutics Market Growth

The systemic lupus erythematous (SLE) category is predicted to account for the biggest market share due to increased approvals of clinical trials for developing SLE treatments. The autoimmune inflammatory illness systemic lupus erythematous (SLE) affects various organs and has a wide range of clinical symptoms. SLE is a type of lupus that affects the joints, skin, brain, lungs, kidneys, and blood vessels by causing tissue damage in the organs involved. The global lupus therapeutics market's manufacturers and players provide treatment therapeutics for a variety of lupus illnesses, including SLE (systemic lupus erythematous).

Growing Emphasis of Major Key Players in North America to Drive Growth Lupus Therapeutics Market

North America dominates the lupus therapeutic market due to the increasing prevalence of lupus in this region. Furthermore, the growing emphasis of major key players on novel technology will accelerate the market's growth rate in this region. Rising investments in high-end, technologically advanced healthcare infrastructure and facilities in developed economies are expected to fuel growth and development in the global lupus therapeutics market in the coming years. According to the Lupus Foundation of America, the year 2019 saw the growth of several companies for lupus treatment, including GSK and Aurinia Pharmaceuticals Inc.

Moreover, the rising prevalence of lupus disorders worldwide is one of the most important factors influencing the growth of the global lupus therapeutics market. For instance, nearly 1.5 million people in the US have some form of lupus, with SLE accounting for 70% of cases, and more than 90% of those diagnosed are women in their adolescent and adult years.

Asia-Pacific is expected to grow during the forecast period due to the region's growing population and rising healthcare expenditure. The growing number of research and drug development as well as drug discovery projects undertaken by industry participants is also influencing the growth of the global lupus therapeutics market. In December 2021, After receiving approval from the Drugs Controller General of India, Biocon Biologics Limited, a subsidiary of the Indian-based biotechnology company Biocon, announced that it has begun a clinical study for its drug Itolizumab for the treatment of Lupus Nephritis. SLE causes Lupus Nephritis, a kidney disease.

Global Lupus Therapeutics Market: Competitive Landscape

Companies in the market are introducing new products alongside initiation collaborations, alliances and partnership agreements. For instance, in January 2022, BenevolentAI, a clinical-stage AI drug discovery business based in the United Kingdom, stated that its collaboration with AstraZeneca for the development of therapeutic medications for the treatment of systemic lupus erythematous and heart failure has been expanded (HF). On the other hand, in December 2020, GlaxoSmithKline plc, a pharmaceutical firm based in the United Kingdom, announced that their medicine BENLYSTA (belimumab) has been approved by the United States Food and Drug Administration (FDA) for use in conjunction with conventional therapy in adult patients. SLE-related active lupus nephritis (LN) is a kidney condition caused by SLE.

A few of the players in the lupus therapeutics market include Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy's Laboratories Ltd., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.

Global Lupus Therapeutics Market is Segmented as Below:

By Disease Type

  • Systemic Lupus Erythematosus (SLE)
  • Cutaneous Lupus Erythematosus
  • Drug-Induced Lupus Erythematosus
  • Neonatal Lupus

By Treatment Type

  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Biologics
  • Antimalarial Drugs
  • Corticosteroids
  • Others (Disease-Modifying Anti-Rheumatic Drugs, Anticoagulants, among others)

By Route of Administration

  • Oral
  • Subcutaneous
  • Intravenous
  • Others (Intramuscular, Intradermal, among others)

By End User

  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others (Homecare, Specialty Centre, among others)

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • France
    • Germany
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Japan
    • South Korea
    • India
    • China
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa

Key Elements Included In The Study: Global Lupus Therapeutics Market

  • Lupus Therapeutics Market by Product/Technology/Grade, Application/End-user, and Region
  • Executive Summary (Opportunity Analysis and Key Trends)
  • Historical Market Size and Estimates, Value, 2018 - 2021
  • Market Value at Regional and Country Level, 2022 - 2029
  • Market Dynamics and Economic Overview
  • Market Size in Value, Growth Rates, and Forecast Figures, 2022 - 2029
  • Competitive Intelligence with Financials, Key Developments, and Portfolio of Leading Companies 
  • Regional and Product/Grade/Application/End-user Price Trends Analysis
  • Value Chain and Five Force’s Analysis
  • Regional/Sub-region/Country Market Size and Trend Analysis
  • Company Market Share Analysis and Key Player Profiles

Post Sale Support, Research Updates & Offerings

We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.

  • The report will be prepared in a PPT format and will be delivered in a PDF format.
  • Additionally, Market Estimation and Forecast numbers will be shared in Excel Workbook.
  • If a report being sold was published over a year ago, we will offer a complimentary copy of the updated research report along with Market Estimation and Forecast numbers within 2-3 weeks’ time of the sale.
  • If we update this research study within the next 2 quarters, post purchase of the report, we will offer a Complimentary copy of the updated Market Estimation and Forecast numbers in Excel Workbook.
  • If there is a geopolitical conflict, pandemic, recession, and the like which can impact global economic scenario and business activity, which might entirely alter the market dynamics or future projections in the industry, we will create a Research Update upon your request at a nominal charge.

Disclaimer:

  • The segmentation/company profiles/countries depicted above may vary in the actual report.

Request Table of Contents

Our Research Methodology

Under uncertainty, traditional approaches to strategic planning can be downright dangerous. True ambiguity is no basis to forecast the future – degree of risk, the magnitude of circumstances, conditions and consequences are not known or unpredictable. To avoid dangerous binary views of uncertainty; strategic posture, moves and actions through market research is the best bet.

Read more
Fairfield Quality assured
Fairfield Confidentiality assured
Fairfield Custom research services